These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 9244149)

  • 1. Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats.
    Srinivas NR; Shyu WC; Weiner RS; Warner G; Comereski C; Tay LK; Greene DS; Barbhaiya RH
    Pharm Res; 1997 Jul; 14(7):911-6. PubMed ID: 9244149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses.
    Srinivas NR; Weiner RS; Warner G; Shyu WC; Davidson T; Fadrowski CG; Tay LK; Lee JS; Greene DS; Barbhaiya RH
    J Pharm Sci; 1996 Jan; 85(1):1-4. PubMed ID: 8926572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice.
    Srinivas NR; Weiner RS; Shyu WC; Calore JD; Tritschler D; Tay LK; Lee JS; Greene DS; Barbhaiya RH
    J Pharm Sci; 1996 Mar; 85(3):296-8. PubMed ID: 8699332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice.
    Srinivas NR; Shyu WC; Weiner RS; Tay LK; Greene DS; Barbhaiya RH
    J Pharm Sci; 1995 Dec; 84(12):1488-9. PubMed ID: 8748333
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
    Siegall CB; Haggerty HG; Warner GL; Chace D; Mixan B; Linsley PS; Davidson T
    J Immunol; 1997 Nov; 159(10):5168-73. PubMed ID: 9366448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac allograft tolerance induced by intra-arterial infusion of recombinant adenoviral CTLA4Ig.
    Yang Z; Rostami S; Koeberlein B; Barker CF; Naji A
    Transplantation; 1999 Jun; 67(12):1517-23. PubMed ID: 10401757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4Ig.
    Feng S; Quickel RR; Hollister-Lock J; McLeod M; Bonner-Weir S; Mulligan RC; Weir GC
    Transplantation; 1999 Jun; 67(12):1607-13. PubMed ID: 10401769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig.
    Perico N; Imberti O; Bontempelli M; Remuzzi G
    Kidney Int; 1995 Jan; 47(1):241-6. PubMed ID: 7731152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
    Brennan BJ; Xu ZX; Grippo JF
    Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression.
    Guillot C; Mathieu P; Coathalem H; Le Mauff B; Castro MG; Tesson L; Usal C; Laumonier T; Brouard S; Soulillou JP; Lowenstein PR; Cuturi MC; Anegon I
    J Immunol; 2000 May; 164(10):5258-68. PubMed ID: 10799887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A sensitive enzyme immunoassay for the quantitation of human CTLA4Ig fusion protein in mouse serum: pharmacokinetic application to optimizing cell line selection.
    Weiner RS; Srinivas NR; Calore JD; Fadrowski CG; Shyu WC; Tay LK
    J Pharm Biomed Anal; 1997 Feb; 15(5):571-9. PubMed ID: 9127268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTLA4Ig inhibits alloantibody responses to repeated blood transfusions.
    Ibrahim S; Jakobs F; Kittur D; Hess A; Linsley PS; Sanfilippo F; Baldwin WM
    Blood; 1996 Dec; 88(12):4594-600. PubMed ID: 8977251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of ethylene glycol. III. Plasma disposition and metabolic fate after single increasing intravenous, peroral, or percutaneous doses in the male Sprague-Dawley rat.
    Frantz SW; Beskitt JL; Tallant MJ; Zourelias LA; Ballantyne B
    Xenobiotica; 1996 May; 26(5):515-39. PubMed ID: 8736063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA4Ig alone or in combination with low-dose cyclosporine fails to reverse acute rejection of renal allograft in the rat.
    Perico N; Amuchastegui S; Bontempelli M; Remuzzi G
    Transplantation; 1996 May; 61(9):1320-2. PubMed ID: 8629290
    [No Abstract]   [Full Text] [Related]  

  • 16. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing.
    Bolling SF; Lin H; Wei RQ; Turka LA
    J Heart Lung Transplant; 1996 Sep; 15(9):928-35. PubMed ID: 8889989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects.
    Khalilieh S; Hodsman P; Xu C; Tzontcheva A; Glasgow S; Montgomery D
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):294-300. PubMed ID: 29510001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371.
    Cho YS; Lim HS; Han S; Yoon SK; Kim H; Cho YL; Nam HS; Bae KS
    Clin Ther; 2019 Jan; 41(1):92-106. PubMed ID: 30559004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of immunosuppression in composite tissue allografts by systemic administration of CTLA4Ig.
    Iwasaki N; Gohda T; Yoshioka C; Murakami M; Inobe M; Minami A; Uede T
    Transplantation; 2002 Feb; 73(3):334-40. PubMed ID: 11884927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.